tiprankstipranks
Athira announces publication on need for novel Alzheimer’s disease treatment
The Fly

Athira announces publication on need for novel Alzheimer’s disease treatment

Athira Pharma announced the publication of a review paper highlighting the need for novel treatment approaches to address Alzheimer’s disease and the therapeutic potential of fosgonimeton, one of the Company’s novel small molecule positive modulators of the HGF/MET system. The review article titled, "The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor Positive Modulators," was published online in the peer-reviewed journal, Journal of Alzheimer’s Disease. "The lack of therapeutic options for patients suffering from Alzheimer’s disease results in significant economic and societal burdens," said Hans Moebius, M.D., Ph.D., Chief Medical Officer of Athira. "In this publication, we review the limitations of the current drug development approaches and discuss the need for additional research efforts that consider the complex AD pathophysiology and incorporate novel study design elements. Taken together, these factors support the advancement of innovative treatment options for Alzheimer’s disease such as Athira’s novel, small molecule positive modulators of the HGF/MET neurotrophic system." In the publication, study authors noted the urgent need to expand the scope of research beyond the "classic hallmarks" of AD, such as amyloid-beta and tau pathologies, and the growing need for novel approaches to clinical trial design, including consideration of recent insights such as proteomics to provide a broader characterization of disease processes. The review also highlights the therapeutic potential of enhancing the activity of the HGF/MET neurotrophic system and provides a summary of the promising preclinical and clinical findings to date with fosgonimeton, a small molecule positive modulator of HGF/MET. Athira is currently evaluating fosgonimeton in the Phase 2/3 LIFT-AD study for mild-to-moderate Alzheimer’s disease. The company expects to complete enrollment of the LIFT-AD study in mid-2023 and to report topline data in early 2024.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ATHA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles